Contemporary Concise Review 2020: Interstitial lung disease

Field	Value	Language
dc.contributor.author	Teoh, Alan K. Y.	en
dc.contributor.author	Corte, Tamera J.	en
dc.date.accessioned	2021-06-02T04:54:44Z
dc.date.available	2021-06-02T04:54:44Z
dc.date.issued	2021
dc.identifier.uri	https://hdl.handle.net/2123/25134
dc.description.abstract	The year 2020 was one like no other, as we witnessed the far-reaching impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) global pandemic. Yet despite an unprecedented and challenging year, global research in interstitial lung disease (ILD) continued to break new grounds. Research progress has led to an improved understanding in new diagnostic tools and potential biomarkers for ILD. Studies on the role of antifibrotic therapies, newer therapeutic agents, supportive care strategies and the impact of coronavirus disease 2019 (COVID-19) continue to reshape the management landscape of ILD. In this concise review, we aim to summarize the key studies published in 2020, highlighting their impact on the various aspects of ILD.	en
dc.language.iso	en	en
dc.rights	Copyright All Rights Reserved	en
dc.subject	COVID-19	en
dc.subject	Coronavirus	en
dc.title	Contemporary Concise Review 2020: Interstitial lung disease	en
dc.type	Article	en
dc.identifier.doi	10.1111/resp.14063
dc.relation.other	Roche (Switzerland)	en
dc.relation.other	Boehringer Ingelheim (Germany)	en
dc.relation.other	National Health and Medical Research Council	en
usyd.faculty	SeS faculties schools::Faculty of Medicine and Health	en

Associated file/s

There are no files associated with this item.